Allelica and Invitae (NVTA) aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic ...

- These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment - SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- ...

Invitae plans to raise $50 million through a secondary common stock. As usual, the underwriters of the deal are also being granted an option to purchase up to an additional $7.5 million worth of stock ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve ...

This episode features Chantelle Schenning, Head of Public Policy at Invitae. Here, she discusses the mission of Invitae, the biggest projects Invitae is currently working on, and more.

SAN FRANCISCO, July 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTAQ), a leading medical genetics company, today announced the launch of its Unlock™ Behind the Seizure ® program, which provides accessible ...

SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a ...

A bankruptcy judge agreed to allow genetics testing company Invitae to start polling creditors on a reorganization plan after altering it to give all unsecured creditors a vote. Judge Michael Kaplan ...

BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical ...